MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the private
placement financing, net
$178,880K
Proceeds from the
pre-closing financing, net
$143,007K
Cash acquired in
connection with the reverse...
$1,269K
Proceeds from early
exercise of options
$5K
Net cash provided by
financing activities
$322,984K
Canceled cashflow
$177K
Net increase in
cash, cash...
$178,533K
Canceled cashflow
$144,451K
Repurchase of equity awards
-$177K
Research and development
license expense
$80,000K
Share-based compensation
expense
$13,300K
Accrued expenses and
other current...
$5,363K
Deposit liability
$5,000K
Deferred revenue
$4,156K
Non-cash interest
expense
$2,185K
Accounts
payable-Nonrelated Party
$2,081K
Non-cash lease expense
$212K
Other assets
-$162K
Depreciation expense
$84K
Net cash used in
investing activities
-$72,919K
Net cash used in
operating activities
-$71,532K
Canceled cashflow
$112,543K
License revenue
$10,844K
Other expense
(income)
-$690K
Purchase of research and
development license
$72,000K
Purchases of property and
equipment
$919K
Net loss
-$153,942K
Canceled cashflow
$11,534K
Accounts receivable
$18,000K
Related party accounts
payable and other...
-$7,081K
Prepaid expenses and
other current assets
$5,015K
Operating lease liability
-$37K
Milestone and license fees
$84,710K
Personnel costs
$31,022K
Research and development
expense-CR001
$25,547K
Professional and other fees
$11,609K
Research and development
expense-CR002
$8,636K
Provision for income taxes
$2,000K
Research and development
expense-Discovery External...
$1,952K
Back
Back
Cash Flow
source: myfinsight.com
CRESCENT BIOPHARMA, INC. (CBIO)
CRESCENT BIOPHARMA, INC. (CBIO)